189 related articles for article (PubMed ID: 28542038)
1. Hypoxia as a target for drug combination therapy of liver cancer.
Bowyer C; Lewis AL; Lloyd AW; Phillips GJ; Macfarlane WM
Anticancer Drugs; 2017 Aug; 28(7):771-780. PubMed ID: 28542038
[TBL] [Abstract][Full Text] [Related]
2. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
Zhou L; Zhao Y; Pan LC; Wang J; Shi XJ; Du GS; He Q
World J Gastroenterol; 2022 Aug; 28(32):4600-4619. PubMed ID: 36157928
[TBL] [Abstract][Full Text] [Related]
4. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
Jiao M; Nan KJ
Int J Oncol; 2012 Feb; 40(2):461-8. PubMed ID: 21922131
[TBL] [Abstract][Full Text] [Related]
5. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma.
Su Q; Fan M; Wang J; Ullah A; Ghauri MA; Dai B; Zhan Y; Zhang D; Zhang Y
Cell Death Dis; 2019 Dec; 10(12):939. PubMed ID: 31819036
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.
Jung EU; Yoon JH; Lee YJ; Lee JH; Kim BH; Yu SJ; Myung SJ; Kim YJ; Lee HS
Cancer Lett; 2010 Dec; 298(1):9-15. PubMed ID: 20573444
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere.
Ma P; Chen J; Qu H; Li Y; Li X; Tang X; Song Z; Xin H; Zhang J; Nai J; Li Z; Wang Z
Drug Deliv; 2020 Dec; 27(1):1412-1424. PubMed ID: 33096947
[TBL] [Abstract][Full Text] [Related]
8. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
9. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
10. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
Hassan S; Peluso J; Chalhoub S; Idoux Gillet Y; Benkirane-Jessel N; Rochel N; Fuhrmann G; Ubeaud-Sequier G
PLoS One; 2020; 15(10):e0240676. PubMed ID: 33052979
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
12. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans.
Kim Y; Jang M; Lim S; Won H; Yoon KS; Park JH; Kim HJ; Kim BH; Park WS; Ha J; Kim SS
Hepatology; 2011 Nov; 54(5):1661-78. PubMed ID: 21748762
[TBL] [Abstract][Full Text] [Related]
13. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
[TBL] [Abstract][Full Text] [Related]
14. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
15. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of hepatitis B virus x protein and hypoxia-inducible factor-1alpha in hepatocellular carcinoma and their possible relationships].
Liu KG; Xie HH; Liu J
Zhonghua Gan Zang Bing Za Zhi; 2007 Feb; 15(2):122-6. PubMed ID: 17362638
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
19. Plantamajoside inhibits the proliferation and epithelial-to-mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia-inducible factor-1α-dependent gene expression.
Yin W; Xu J; Li C; Dai X; Wu T; Wen J
Cell Biol Int; 2020 Aug; 44(8):1616-1627. PubMed ID: 32239594
[TBL] [Abstract][Full Text] [Related]
20. Combining combretastatin A4 phosphate with ginsenoside Rd synergistically inhibited hepatocellular carcinoma by reducing HIF-1α via PI3K/AKT/mTOR signalling pathway.
Yang X; Gao M; Miao M; Jiang C; Zhang D; Yin Z; Ni Y; Chen J; Zhang J
J Pharm Pharmacol; 2021 Mar; 73(2):263-271. PubMed ID: 33793802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]